Ticagrelor in Triple Antithrombotic Therapy: Predictors of Ischemic and Bleeding Complications
Clinical Cardiology2016Vol. 39(1), pp. 19–23
Citations Over TimeTop 10% of 2016 papers
Angel Fu, Kuljit Singh, Joseph Abunassar, Nikita Malhotra, Michel Le May, Marino Labinaz, Christopher Glover, Jean-François Marquis, Michael Froeschl, Alexander Dick, Benjamin Hibbert, Aun‐Yeong Chong, Derek So, on behalf of the CAPITAL Investigators
Abstract
The risk of bleeding and ischemic complications among patients on TT is similar between those on ticagrelor and clopidogrel. However, caution with use of bridging anticoagulation should be taken when using ticagrelor.
Related Papers
- → Development and Clinical use of Prasugrel and Ticagrelor(2012)29 cited
- → Inter-patient variability of platelet reactivity in patients treated with prasugrel and ticagrelor(2015)31 cited
- → Treating acute coronary syndromes with new antiplatelet drugs: the mortality issue with prasugrel and ticagrelor(2011)6 cited
- → Prasugrel vs. Ticagrelor in acute coronary syndromes: Which one to choose?(2011)5 cited
- → TCTAP A-027 Comparison of On-treatment Platelet Reactivity After One-month Use of Clopidogrel, Prasugrel or Ticagrelor in Koreans with Acute Coronary Syndromes(2014)2 cited